Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Regulation of dimethyl-fumarate toxicity by proteasome inhibitors.
The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
CinnoVex home page
Rituximab for relapsing-remitting multiple sclerosis.
Eosinophilic Fasciitis-like Disorder Developing in the Setting of Multiple Sclerosis Therapy.
Dimethylfumarate induces apoptosis in human mast cells.
The Correlation between the Virus- and Brain Antigen-Specific B Cell Response in the Blood of Patients with Multiple Sclerosis.
Association Between Sleep Problems and Perceived Cognitive Dysfunction Over 12 Months in Individuals with Multiple Sclerosis.
Episode 21 with Dr. Paul Matthews discussing imaging in MS
Overview of the immune system.
[The overall assessment of the quality of the physical health of patients with multiple sclerosis after the application of physical therapy. Part 1].
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Brain-gut axis and pentadecapeptide BPC 157. Theoretical and practical implications.
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Alpha/beta interferon is a neuronal growth factor.
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Keystone Symposium on the Gut Microbiome: The Effector/Regulatory Immune Network
Betaseron (Interferon Beta-1b) for SC Injection
Sema4A inhibits the therapeutic effect of IFN-β in EAE.
Policy: NIH to balance sex in cell and animal studies.
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Pages